Loading…
Greenwich LifeSciences, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in GLSI.
▼ -48.5% over 5Y.
today you would have $466.34▼ -53.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $21.01 | $11.23 | $10.52 | $15.20 | $24.33 | $36.47 | |
| P/B | 18.6x | 873.1x | 164.1x | 20.2x | 14.8x | 11.7x | 17.0x |
| EPS | -$1.43 | -$1.34 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | |
| ROE | -95.96% | -5480.55% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KROSKeros Therapeutics, Inc. | $11.63 | — | 0.9x | — | -17.16% | $230.59M |
| ELMDElectromed, Inc. | $27.57 | 21.2x | 4.3x | — | 23.26% | $230.66M |
| AVXLAnavex Life Sciences Corp | $2.47 | — | 2.0x | — | -12.80% | $228.96M |
| UTMDUtah Medical Products Inc | $72.77 |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Company description provided by Yahoo Finance.
| -1916.54% |
| -132.71% |
| -59.22% |
| -17.03% |
| -6.74% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 22.2x |
| 1.9x |
| 1.70% |
| 8.76% |
| $231.69M |
| TNXPTonix Pharmaceuticals Holding Corp. | $13.59 | — | 1.0x | — | -81.82% | $233.08M |
| RNAAtrium Therapeutics, Inc. | $13.64 | — | 1.0x | — | — | $233.32M |